123 related articles for article (PubMed ID: 29878361)
1. Association between Ki-67 expression and clinical outcomes among patients with clinically node-negative, thick primary melanoma who underwent nodal staging.
Robinson EM; Rosenbaum BE; Zhang Y; Rogers R; Tchack J; Berman RS; Darvishian F; Osman I; Shapiro RL; Shao Y; Polsky D
J Surg Oncol; 2018 Jul; 118(1):150-156. PubMed ID: 29878361
[TBL] [Abstract][Full Text] [Related]
2. Ki-67 expression in melanoma. A potential method of risk assessment for the patient with a positive sentinel node.
Pearl RA; Pacifico MD; Richman PI; Stott DJ; Wilson GD; Grobbelaar AO
J Exp Clin Cancer Res; 2007 Mar; 26(1):109-15. PubMed ID: 17550139
[TBL] [Abstract][Full Text] [Related]
3. Tumor mitotic rate added to the equation: melanoma prognostic factors changed? : a single-institution database study on the prognostic value of tumor mitotic rate for sentinel lymph node status and survival of cutaneous melanoma patients.
Speijers MJ; Bastiaannet E; Sloot S; Suurmeijer AJ; Hoekstra HJ
Ann Surg Oncol; 2015 Sep; 22(9):2978-87. PubMed ID: 25605514
[TBL] [Abstract][Full Text] [Related]
4. Patterns of initial recurrence and prognosis after sentinel lymph node biopsy and selective lymphadenectomy for melanoma.
Wagner JD; Ranieri J; Evdokimow DZ; Logan T; Chuang TY; Johnson CS; Jung SH; Wenck S; Coleman JJ
Plast Reconstr Surg; 2003 Aug; 112(2):486-97. PubMed ID: 12900606
[TBL] [Abstract][Full Text] [Related]
5. Microphthalmia transcription factor in malignant melanoma predicts occult sentinel lymph node metastases and survival.
Naffouje S; Naffouje R; Bhagwandin S; Salti GI
Melanoma Res; 2015 Dec; 25(6):496-502. PubMed ID: 26317170
[TBL] [Abstract][Full Text] [Related]
6. Sentinel-node biopsy or nodal observation in melanoma.
Morton DL; Thompson JF; Cochran AJ; Mozzillo N; Elashoff R; Essner R; Nieweg OE; Roses DF; Hoekstra HJ; Karakousis CP; Reintgen DS; Coventry BJ; Glass EC; Wang HJ;
N Engl J Med; 2006 Sep; 355(13):1307-17. PubMed ID: 17005948
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors in melanoma patients with tumor-negative sentinel lymph nodes.
Egger ME; Bhutiani N; Farmer RW; Stromberg AJ; Martin RC; Quillo AR; McMasters KM; Scoggins CR
Surgery; 2016 May; 159(5):1412-21. PubMed ID: 26775577
[TBL] [Abstract][Full Text] [Related]
8. The Prognostic Significance of Sentinel Lymph Node Status for Patients with Thick Melanoma.
Bello DM; Han G; Jackson L; Bulloch K; Ariyan S; Narayan D; Rothberg BG; Han D
Ann Surg Oncol; 2016 Dec; 23(Suppl 5):938-945. PubMed ID: 27527717
[TBL] [Abstract][Full Text] [Related]
9. Examination of regional lymph nodes by sentinel node biopsy and molecular analysis provides new staging facilities in primary cutaneous melanoma.
Blaheta HJ; Ellwanger U; Schittek B; Sotlar K; MacZey E; Breuninger H; Thelen MH; Bueltmann B; Rassner G; Garbe C
J Invest Dermatol; 2000 Apr; 114(4):637-42. PubMed ID: 10733666
[TBL] [Abstract][Full Text] [Related]
10. Sentinel Lymph Node Biopsy Provides Prognostic Value in Thick Head and Neck Melanoma.
Monroe MM; Pattisapu P; Myers JN; Kupferman ME
Otolaryngol Head Neck Surg; 2015 Sep; 153(3):372-8. PubMed ID: 26070510
[TBL] [Abstract][Full Text] [Related]
11. Sentinel lymph node biopsy is indicated for patients with thick clinically lymph node-negative melanoma.
Yamamoto M; Fisher KJ; Wong JY; Koscso JM; Konstantinovic MA; Govsyeyev N; Messina JL; Sarnaik AA; Cruse CW; Gonzalez RJ; Sondak VK; Zager JS
Cancer; 2015 May; 121(10):1628-36. PubMed ID: 25677366
[TBL] [Abstract][Full Text] [Related]
12. Sentinel Lymph Node Biopsy in Thick-Melanoma Patients (N=350): What is Its Prognostic Role?
Ribero S; Osella-Abate S; Sanlorenzo M; Balagna E; Senetta R; Fierro MT; Macripò G; Macrì L; Sapino A; Quaglino P
Ann Surg Oncol; 2015; 22(6):1967-73. PubMed ID: 25388059
[TBL] [Abstract][Full Text] [Related]
13. Sentinel lymph node status is the most important prognostic factor for thick (> or = 4 mm) melanomas.
Gutzmer R; Satzger I; Thoms KM; Völker B; Mitteldorf C; Kapp A; Bertsch HP; Kretschmer L
J Dtsch Dermatol Ges; 2008 Mar; 6(3):198-203. PubMed ID: 18093216
[TBL] [Abstract][Full Text] [Related]
14. Practice Patterns and Prognostic Value of Sentinel Lymph Node Biopsy for Thick Melanoma: A National Cancer Database Study.
Song Y; Azari FS; Metzger DA; Fraker DL; Karakousis GC
Ann Surg Oncol; 2019 Dec; 26(13):4651-4662. PubMed ID: 31485823
[TBL] [Abstract][Full Text] [Related]
15. The survival benefit to patients with positive sentinel node melanoma after completion lymph node dissection may be limited to the subgroup with a primary lesion Breslow thickness greater than 1.0 and less than or equal to 4 mm (pT2-pT3).
Nowecki ZI; Rutkowski P; Michej W
Ann Surg Oncol; 2008 Aug; 15(8):2223-34. PubMed ID: 18506535
[TBL] [Abstract][Full Text] [Related]
16. Sentinel lymph node biopsy in thick malignant melanoma: a 10-year single unit experience.
Fairbairn NG; Orfaniotis G; Butterworth M
J Plast Reconstr Aesthet Surg; 2012 Oct; 65(10):1396-402. PubMed ID: 22552263
[TBL] [Abstract][Full Text] [Related]
17. Surgical management of the groin lymph nodes in melanoma in the era of sentinel lymph node dissection.
Essner R; Scheri R; Kavanagh M; Torisu-Itakura H; Wanek LA; Morton DL
Arch Surg; 2006 Sep; 141(9):877-82; discussion 882-4. PubMed ID: 16983031
[TBL] [Abstract][Full Text] [Related]
18. Clinical impact of sentinel lymph node biopsy in patients with thick (>4 mm) melanomas.
White I; Fortino J; Curti B; Vetto J
Am J Surg; 2014 May; 207(5):702-7; discussion 707. PubMed ID: 24791630
[TBL] [Abstract][Full Text] [Related]
19. Sentinel lymph node staging of cutaneous melanoma: predictors and outcomes.
Ellis MC; Weerasinghe R; Corless CL; Vetto JT
Am J Surg; 2010 May; 199(5):663-8. PubMed ID: 20466113
[TBL] [Abstract][Full Text] [Related]
20. Sentinel Lymph Node Biopsy in T4 Melanoma: An Important Risk-Stratification Tool.
Gyorki DE; Sanelli A; Herschtal A; Lazarakis S; McArthur GA; Speakman D; Spillane J; Henderson MA
Ann Surg Oncol; 2016 Feb; 23(2):579-84. PubMed ID: 26471491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
